Copy

Health Matters: Thinking Through Infectious Disease Risk

HAVEN'S WEEKLY TAKEAWAYS

September 10, 2020
  • JPMorgan is noticing that productivity is down "in general, not just younger employees"
  • One Vanderbilt, $3.3B development, officially opened in New York City as a sign of hope for the office market
  • Haven Diagnostics’ internal conversations suggest companies are targeting 1Q21 return to office dates; physical occupancy in New York City hovers around 7% post-Labor Day.
  • Eli Lilly therapeutic showing positive results
  • Big Ten football set to resume October 23 weekend
  • Israel locks down its country for the second time due to a resurgence in cases
  • Dr. Robert Redfield 'masks are the most important, powerful tool'
  • Europe faces grave concern; W.H.O. calls for action in Madrid
READ FULL REPORT

In this issue:

  • DOMESTIC UPDATES
  • COVID-19 VACCINE UPDATES
  • GLOBAL UPDATES

DOMESTIC UPDATE

Curve: Deaths Near 200,000 In The US

Back-to-back days of 1,000+ deaths and monitoring post-Labor Day hospitalizations will be an important indicator as we move into the middle of September (NPR)
 

First Major Bank Delays Re-Entry Until 2Q21

Deutsche Bank announces July 2021 date for employees return to work in NYC which coincides with their HQ opening in Columbus Circle (Bloomberg)


Administration Offers Widescale Distribution Approach for COVID-19 Vaccine

Two-shot approach for most vaccines and both doses will have to be from the same drugmaker; Phase one of the distribution will focus on health care workers; States and local governments have one month to submit receivership plans; Vaccine will be funded by taxpayers (AP News)

TREATMENT AND DIAGNOSIS

AZN Resumes Trial in the U.K.; Pfizer Expands Phase 3 trials; Eli Lilly Therapeutic Shows a Reduction in COVID

Oxford University and AstraZeneca AZD 1222 clinical trials have resumed in the U.K. following a potential scare; the trial has not resumed in the U.S. yet as NIH investigates the trial incident (Reuters)

Pfizer and BioNTech expanded their phase 3 trial to 44,000 participants in the U.S.; their vaccine could be ready for FDA review by the end of October; the vaccine, two-dose, the trial has shown mild-to-moderate side effects in 12,000 participants thus far (BioSpace)

Eli Lilly and AbCellera's therapeutic, LY-Cov555, showed positive results in clinical patients. The single infusion cut hospitalizations and emergency room visits for moderate COVID-19 cases. The sample size was <1,000 so we continue to monitor this news (BioSpace)

GLOBAL UPDATES

Israel Shuts Down for the Second Time

Israel locks down its country for the second time due to a resurgence in cases; the country will remain closed for three weeks as it struggles to contain the virus (WSJ)

Europe Teetering on the Brink of a Second Wave

Cases in France soar past 10,000 per day and the number of hospitalizations has doubled in just nine days; the city of Bordeaux nears ICU capacity; Spain surpasses 30,000 deaths and 600,000 cases and Madrid may face a second shut down; Austria tightens measures to control spread (France 24; Telegraph)

READ FULL REPORT

Michael Gao, M.D.
CEO and Founder, Haven Diagnostics
Board-certified Physician and Data Scientist
Currently on faculty at Weill Cornell
Previously Medical Director of Transformation at NewYork-Presbyterian

Building technology to help you understand and communicate your property's infectious disease risk to existing and prospective tenants.

LinkedIn
Twitter
Facebook
Website
Email
Copyright © 2020 Haven Diagnostics, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp